Abbott Laboratories Return on Tangible Equity 2010-2025 | ABT
Current and historical return on tangible equity values for Abbott Laboratories (ABT) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
| Abbott Laboratories Return On Tangible Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Tangible Equity | Return on Tangible Equity |
| 2025-03-31 | $13.50B | $19.44B | 98.14% |
| 2024-12-31 | $13.40B | $18.15B | 124.81% |
| 2024-09-30 | $5.77B | $9.02B | 74.08% |
| 2024-06-30 | $5.56B | $8.43B | 81.55% |
| 2024-03-31 | $5.63B | $7.36B | 97.30% |
| 2023-12-31 | $5.72B | $6.33B | 114.01% |
| 2023-09-30 | $5.16B | $5.14B | 118.68% |
| 2023-06-30 | $5.16B | $4.31B | 137.51% |
| 2023-03-31 | $5.80B | $4.30B | 177.48% |
| 2022-12-31 | $6.93B | $3.65B | 307.89% |
| 2022-09-30 | $7.89B | $2.75B | 583.40% |
| 2022-06-30 | $8.55B | $2.38B | 4987.76% |
| 2022-03-31 | $7.73B | $0.23B | -639.62% |
| 2021-12-31 | $7.07B | $0.05B | -320.21% |
| 2021-09-30 | $7.24B | $-1.97B | -201.05% |
| 2021-06-30 | $6.38B | $-3.14B | -131.53% |
| 2021-03-31 | $5.72B | $-3.78B | -94.14% |
| 2020-12-31 | $4.50B | $-5.53B | -61.35% |
| 2020-09-30 | $3.38B | $-6.95B | -41.37% |
| 2020-06-30 | $3.11B | $-8.07B | -36.33% |
| 2020-03-31 | $3.58B | $-8.77B | -40.10% |
| 2019-12-31 | $3.69B | $-8.92B | -39.34% |
| 2019-09-30 | $3.29B | $-8.49B | -32.88% |
| 2019-06-30 | $2.90B | $-9.53B | -26.59% |
| 2019-03-31 | $2.62B | $-10.55B | -22.29% |
| 2018-12-31 | $2.37B | $-11.47B | -18.92% |
| 2018-09-30 | $0.89B | $-12.00B | -6.69% |
| 2018-06-30 | $0.93B | $-13.02B | -7.50% |
| 2018-03-31 | $0.48B | $-13.57B | -4.20% |
| 2017-12-31 | $0.48B | $-14.40B | -4.65% |
| 2017-09-30 | $2.10B | $-8.43B | -46.38% |
| 2017-06-30 | $1.17B | $-9.00B | -359.48% |
| 2017-03-31 | $1.50B | $-9.21B | 44.78% |
| 2016-12-31 | $1.40B | $8.50B | 19.83% |
| 2016-09-30 | $1.37B | $8.41B | 21.16% |
| 2016-06-30 | $2.28B | $5.73B | 39.46% |
| 2016-03-31 | $2.45B | $5.61B | 39.46% |
| 2015-12-31 | $4.42B | $6.13B | 69.79% |
| 2015-09-30 | $4.56B | $5.63B | 74.17% |
| 2015-06-30 | $4.52B | $7.45B | 70.00% |
| 2015-03-31 | $4.20B | $6.15B | 62.46% |
| 2014-12-31 | $2.28B | $5.37B | 31.67% |
| 2014-09-30 | $1.97B | $6.85B | 23.70% |
| 2014-06-30 | $2.40B | $8.53B | 27.78% |
| 2014-03-31 | $2.41B | $8.10B | 28.81% |
| 2013-12-31 | $2.58B | $9.76B | 31.68% |
| 2013-09-30 | $3.04B | $8.14B | 48.21% |
| 2013-06-30 | $4.02B | $7.43B | 82.32% |
| 2013-03-31 | $5.27B | $7.20B | 170.94% |
| 2012-12-31 | $5.96B | $2.45B | 480.21% |
| 2012-09-30 | $6.53B | $2.44B | 1938.83% |
| 2012-06-30 | $4.89B | $0.23B | -571.14% |
| 2012-03-31 | $5.11B | $-0.15B | -359.46% |
| 2011-12-31 | $4.73B | $-1.17B | -196.08% |
| 2011-09-30 | $4.55B | $-2.34B | -131.96% |
| 2011-06-30 | $5.14B | $-2.03B | -111.53% |
| 2011-03-31 | $4.49B | $-4.12B | -85.92% |
| 2010-12-31 | $4.63B | $-5.32B | -86.34% |
| 2010-09-30 | $4.73B | $-6.97B | -152.11% |
| 2010-06-30 | $5.31B | $-4.49B | -839.83% |
| 2010-03-31 | $5.31B | $-4.66B | 579.54% |
| 2009-12-31 | $5.75B | $3.70B | 267.47% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $232.407B | $41.950B |
| Abbott Labs discovers, develops, manufactures & sells a diversified line of health care products. Established Pharmaceuticals Division includes branded generics business in the emerging markets. Medical Devices unit includes the diabetes care, vision care & vascular businesses. Diagnostics unit manufactures and markets diagnostic systems and tests in four business lines core laboratory, molecular, point of care and rapid diagnostics. Nutrition unit includes a broad line of pediatric and adult nutritional products. Abbott acquired CFR Pharmaceuticals, Tendyne Holdings, Inc., St. Jude Medical and Alere Inc. On the other hand, Abbott sold its developed markets branded generics pharmaceuticals business to Mylan. Abbott retained the branded generics pharmaceuticals business in emerging markets. Abbott sold its animal health business to Zoetis Inc and divested its vision care business, Medical Optics, to Johnson & Johnson. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Boston Scientific (BSX) | United States | $151.037B | 37.81 |
| Stryker (SYK) | United States | $146.527B | 30.64 |
| EssilorLuxottica (ESLOY) | France | $129.703B | 0.00 |
| Medtronic (MDT) | Ireland | $112.146B | 15.90 |
| Lonza Group Ag (LZAGY) | Switzerland | $50.313B | 0.00 |
| Haleon (HLN) | United Kingdom | $49.826B | 28.39 |
| ResMed (RMD) | United States | $36.979B | 27.77 |
| Agilent Technologies (A) | United States | $32.895B | 21.44 |
| GE HealthCare Technologies (GEHC) | United States | $32.794B | 15.57 |
| Terumo (TRUMY) | Japan | $26.561B | 34.50 |
| Koninklijke Philips (PHG) | Netherlands | $22.051B | 15.85 |
| Insulet (PODD) | United States | $21.941B | 86.12 |
| Zimmer Biomet Holdings (ZBH) | United States | $18.277B | 11.74 |
| Baxter (BAX) | United States | $15.529B | 11.59 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $13.253B | 0.00 |
| Demant (WILYY) | Denmark | $8.854B | 0.00 |
| Sunny Optical Technology (SNPTF) | China | $8.430B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $5.971B | 20.78 |
| Lantheus Holdings (LNTH) | United States | $5.642B | 14.23 |
| Prestige Consumer Healthcare (PBH) | United States | $4.203B | 18.78 |
| Perrigo (PRGO) | Ireland | $3.596B | 9.11 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| Haemonetics (HAE) | United States | $3.385B | 15.42 |
| ICU Medical (ICUI) | United States | $3.275B | 24.15 |
| Envista Holdings (NVST) | United States | $3.174B | 26.38 |
| GN Store Nord (GNNDY) | Denmark | $2.180B | 18.06 |
| QuidelOrtho (QDEL) | United States | $1.997B | 13.73 |
| LeMaitre Vascular (LMAT) | United States | $1.901B | 42.49 |
| AtriCure (ATRC) | United States | $1.730B | 0.00 |
| Acuren (TIC) | United States | $1.271B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.201B | 12.19 |
| Neogen (NEOG) | United States | $1.131B | 14.47 |
| BioLife Solutions (BLFS) | United States | $1.126B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.100B | 24.74 |
| Kestra Medical Technologies (KMTS) | United States | $1.063B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $0.976B | 12.48 |
| InMode (INMD) | Israel | $0.895B | 9.02 |
| Capricor Therapeutics (CAPR) | United States | $0.650B | 0.00 |
| Evolus (EOLS) | United States | $0.647B | 0.00 |
| CeriBell (CBLL) | United States | $0.647B | 0.00 |
| Owens & Minor (OMI) | United States | $0.619B | 5.13 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.609B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $0.584B | 0.00 |
| Valneva SE (VALN) | France | $0.524B | 0.00 |
| Surmodics (SRDX) | United States | $0.420B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.408B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.347B | 12.76 |
| SNDL (SNDL) | Canada | $0.347B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.322B | 57.20 |
| Canopy Growth (CGC) | Canada | $0.313B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.291B | 0.00 |
| Cerus (CERS) | United States | $0.289B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.266B | 22.40 |
| Cresco Labs (CRLBF) | United States | $0.265B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.262B | 0.00 |
| ZimVie (ZIMV) | United States | $0.261B | 11.87 |
| Sanuwave Health (SNWV) | United States | $0.239B | 0.00 |
| Omeros (OMER) | United States | $0.221B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.216B | 0.00 |
| Biote (BTMD) | United States | $0.210B | 5.89 |
| Quanterix (QTRX) | United States | $0.209B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.204B | 0.00 |
| Brainsway (BWAY) | Israel | $0.197B | 52.25 |
| High Tide (HITI) | Canada | $0.193B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.192B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.182B | 14.86 |
| Organigram Global (OGI) | Canada | $0.181B | 0.00 |
| Exagen (XGN) | United States | $0.154B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.139B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.134B | 0.00 |
| Jin Medical (ZJYL) | China | $0.120B | 0.00 |
| MacroGenics (MGNX) | United States | $0.112B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.091B | 0.00 |
| Veru (VERU) | United States | $0.091B | 0.00 |
| Fonar (FONR) | United States | $0.090B | 11.59 |
| Quipt Home Medical (QIPT) | United States | $0.087B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.082B | 0.00 |
| Agape ATP (ATPC) | $0.077B | 0.00 | |
| InterCure (INCR) | Israel | $0.068B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.066B | 0.00 |
| Zynex (ZYXI) | United States | $0.066B | 0.00 |
| Apyx Medical (APYX) | United States | $0.063B | 0.00 |
| ImmuCell (ICCC) | United States | $0.059B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.058B | 0.00 |
| Modular Medical (MODD) | United States | $0.046B | 0.00 |
| United-Guardian (UG) | United States | $0.038B | 13.14 |
| Nephros (NEPH) | United States | $0.036B | 48.00 |
| Rockwell Medical (RMTI) | United States | $0.035B | 0.00 |
| Safety Shot (SHOT) | United States | $0.020B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.020B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.019B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.017B | 0.00 |
| INLIF (INLF) | $0.016B | 0.00 | |
| Flora Growth (FLGC) | United States | $0.014B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.012B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.009B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.006B | 0.00 |
| Senestech (SNES) | United States | $0.005B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.004B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| Sharps Technology (STSS) | United States | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |